Roche (RHHBY) Stock Forecast & Price Target

$40.14

-0.02 (-0.05%)

(As of 09/27/2024 ET)

Roche - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 5 Analyst Ratings

Sell
3

Hold
1

Buy
1

Based on 5 Wall Street analysts who have issued ratings for Roche in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 5 analysts, 3 have given a sell rating, 1 has given a hold rating, and 1 has given a buy rating for RHHBY.

Consensus Price Target

N/A

Get the Latest News and Ratings for RHHBY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Roche and its competitors.

RHHBY Analyst Ratings Over Time

Type	Current Forecast 9/30/23 to 9/29/24	1 Month Ago 8/31/23 to 8/30/24	3 Months Ago 7/2/23 to 7/1/24	1 Year Ago 9/30/22 to 9/30/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	0 Buy rating(s)	1 Buy rating(s)	2 Buy rating(s)
Hold	1 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)	9 Hold rating(s)
Sell	3 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	N/A	$40.00	$40.00	$45.33
Forecasted Upside	N/A	-5.50% Downside	15.47% Upside	33.61% Upside
Consensus Rating	Reduce	Reduce	Reduce	Hold

WARNING: “Buffett Indicator” flashing for first time in 50 years (Ad)

The stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.

Take these 4 steps today to protect your retirement NOW

RHHBY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RHHBY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Roche Stock vs. The Competition

Type	Roche	Medical Companies	S&P 500
Consensus Rating Score	1.60	2.78	2.50
Consensus Rating	Reduce	Moderate Buy	Hold
Predicted Upside	N/A	818.50% Upside	6.15% Upside
News Sentiment Rating	Neutral News See Recent RHHBY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
9/13/2024	Deutsche Bank Aktiengesellschaft 3 of 5 stars	Downgrade	Hold ➝ Sell
9/13/2024	Bank of America 4 of 5 stars	Upgrade	Neutral ➝ Buy
5/30/2024	The Goldman Sachs Group 2 of 5 stars	Initiated Coverage	Sell
3/4/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
1/16/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Equal Weight ➝ Underweight
9/12/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Market Perform ➝ Market Perform	$45.00 ➝ $40.00	+12.71%
9/5/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
3/27/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight
2/27/2023	Societe Generale Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
1/4/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
1/3/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underweight
12/14/2022	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	CHF 328 ➝ CHF 329
11/15/2022	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
11/15/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$48.00	+16.31%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:35 AM ET.

RHHBY Forecast - Frequently Asked Questions

: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Roche in the last twelve months. There are currently 3 sell ratings, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" RHHBY shares.
: According to analysts, Roche's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.
: Over the previous 90 days, Roche's stock had 1 upgrade and 1 downgrade by analysts.
: Roche has been rated by research analysts at Bank of America, and Deutsche Bank Aktiengesellschaft in the past 90 days.
: Analysts like Roche less than other "medical" companies. The consensus rating for Roche is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RHHBY compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

NOTICE: You have until Tuesday, November 19th (Ad)

On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy...

Click here for the ticker >>>

This page (OTCMKTS:RHHBY) was last updated on 9/29/2024 by MarketBeat.com Staff

From Our Partners